Octagon Capital Advisors’s Kyntra Bio KYNB Stock Holding History

Octagon Capital Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,841	Closed	-$5.42M	–	32
2020 Q4	$5.42M	Buy	+5,841	New	+$6.14M	1.88%	17

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Octagon Capital Advisors's KYNB Position: Q1 2021 in Review

Octagon Capital Advisors sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 5,841 shares — an estimated $5.42M sold.

Octagon Capital Advisors first reported a position in KYNB in Q4 2020 and held it in 1 quarter. The position peaked at $5.42M in Q4 2020. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

Octagon Capital Advisors reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
Octagon Capital Advisors sold 5,841 Kyntra Bio shares in Q1 2021, an estimated $5.42M.
Octagon Capital Advisors first reported a position in Kyntra Bio in Q4 2020 and held it in 1 quarter.
Octagon Capital Advisors's Kyntra Bio position peaked at $5.42M in Q4 2020.
198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Octagon Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.